Close Menu

IPO

NEW YORK (GenomeWeb News) – AutoGenomics once again withdrew its planned initial public offering after failing to meet a Feb. 15 deadline to provide its latest financial information to the US Securities and Exchange Commission, a company official confirmed to GenomeWeb Daily News.

NEW YORK (GenomeWeb News) – Cancer Genetics has again lowered the amount it expects to bring in from its pending initial public offering, the Rutherford, NJ-based firm disclosed in a document filed with the US Securities and Exchange Commission late on Wednesday.

NEW YORK (GenomeWeb News) – Cancer Genetics plans to raise more than $29 million from its initial public offering, the company said in its amended Form S-1 yesterday.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm AutoGenomics lowered the net proceeds it expects from a planned initial public offering to $53.7 million, it said in an amended Form S-1 filed with the US Securities and Exchange Commission on Wednesday.

NEW YORK (GenomeWeb News) – Arrayit Corp. today said that its majority-owned subsidiary Arrayit Diagnostics has filed a Form S-1 with the US Securities and Exchange Commission, which would allow it to become an independently traded company.

NEW YORK (GenomeWeb News) – Atossa Genetics on Thursday priced its initial public offering of 800,000 shares at $5 per share, raising gross proceeds of $4 million.

NEW YORK (GenomeWeb News) – Atossa Genetics, which refiled for an initial public offering earlier this year after withdrawing from an earlier attempt, today revised the estimate on how much the offering may garner.

NEW YORK (GenomeWeb News) – Atossa Genetics has increased to 1.3 million the number of shares it plans to offer in its initial public offering, the firm said in a document filed with the US Securities and Exchange Commission on Friday.

Shares of Regulus Therapeutics fell back near their already-reduced initial public offering level this week, suggesting that Wall Street may be less willing to embrace microRNA therapeutics than may have been anticipated.

Regulus Therapeutics, the microRNA drugs joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week disclosed that it is pricing its initial public offering of 11.25 million shares at $4 a share, for a total value of $45 million.

Pages

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.